Abstract:Background: In order to optimize positioning and associated drug price for both payer and investor, it is for a company essential to forecast the potential market access attractiveness for the new drug for different indications at the early onset of the clinical development program. This analysis must include the constraints from the perspective of the payer, but also the biotech companies, who require a minimum drug price to satisfy their investors. This paper aims to provide an Integrated Valuation Model for payer and investor, bridging concepts from health economics and economic valuation reflecting the perspectives of the payer and the investor for a drug in early clinical development phase. The concept is illustrated for a new hypothetical drug (Product X) in advanced breast cancer in 1-line, 2-line, and 3-line position. Methods: The Integrated Valuation Model includes the outcomes of the budget impact model, pricing matrix model, and cost-effectiveness model reflecting the payer's perspective. These models are interacted and linked with a discounted cash flow model in order to reflect also the economic value from the investor's perspective. Results: The maximum price in 1-line position is €269.7 for the payer and the minimum price is €14.7 for the investor, which are unit prices per administration corresponding with treatment regimens for the comparative treatments. In 2-line position, the maximum price is €274.1 for the payer and the minimum price for the investor increases to €184.5 for the investor because of the smaller market size in 2-line position, which leads to a smaller pricing corridor to satisfy both payer and investor. Consequently, Product X has market access attractiveness for both payer and investor in 1-line and 2-line position. However, the minimum price €942.7 in 3-line position for the investor is higher than the maximum price €283.3 for the payer, which means there is no market potential. Conclusion: The practical strategic application of the Integrated Valuation Model is optimization of positioning and price of Product X. Hence, it can be a transparent tool in early-stage development of a compound based on upfront assessment of market access attractiveness for the payer and the investor.

Pharmacoeconomic Analysis in New Drug Development: A Pragmatic Approach to Efficiency Studies

Application of Path Analysis in Pharmacoeconomics

Question-based drug development and the value of novel treatments

The Application of Pharmacoeconomics in Clinical Medicine Decision Making

Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact

Guidelines for Pharmacoeconomic Studies

A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.

Price Models for Multi-indication Drugs: A Systematic Review

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS

A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application

An integrated valuation model for payer and investor

Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice.

Real World Study and Pharmacoeconomic Evaluation

Drug pricing models, no 'one-size-fits-all' approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape

Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases

Adaptive seamless design for establishing pharmacokinetics and efficacy equivalence in developing biosimilars

Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis

Rational Clinical Drug Use Under the Guidance of Pharmacoeconomic Theory

Application of the Price–Volume Approach in Cases of Innovative Drugs Where Value-Based Pricing is Inadequate: Description of Real Experiences in Italy

Flexible Approaches Based on Multistate Models and Microsimulation to Perform Real-World Cost-Effectiveness Analyses: An Application to Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors